Key events in the second fiscal quarter
Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter.
- The company expects a data readout for Lynparza in an ovarian cancer indication.
- A regulatory decision is expected for Tagrisso in the European Union for lung cancer.
- A regulatory decision is expected for Lokelma for hyperkalemia in the United States.
- A regulatory submission for Duaklir for chronic obstructive pulmonary disease is expected in the United States.
Events expected in the second half of fiscal 2018
In the second half of fiscal 2018, AstraZeneca expects a slew of events with regards to Lynparza, Tagrisso, Imfinzi, Farxiga, Bydureon, and Bevespi. The company expects a regulatory decision in Japan for Lynparza in a breast cancer indication and a regulatory submission for Lynparza as a first-line treatment for ovarian cancer. It also expects a regulatory decision in Japan for Tagrisso for lung cancer.
Several developments are expected for AstraZeneca’s Imfinzi. The company expects regulatory decisions in Europe and Japan for Imfinzi for lung cancer, and a data readout and regulatory submission from the MYSTIC trial, which is testing Imfinzi as a first-line treatment for lung cancer. A data readout is also expected from the KESTREL trial for head and neck cancer with Imfinzi as a first-line treatment. AstraZeneca also expects a data readout and regulatory submission from the EAGLE trial, which is testing Imfinzi as a second-line treatment for head and neck cancer.
AstraZeneca expects a data readout and regulatory submission for selumetinab indicated for thyroid cancer, and a regulatory decision in the United States for moxetumomab pasudutox as a third-line treatment for hairy cell leukemia. In the next part of this series, we’ll look at more key events to watch for in AstraZeneca’s research pipeline.